Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Murray, Nigel P ^a,b,c   Reyes, Eduardo ^a,d   Orellana, Nelson ^a   Fuentealba, Cynthia ^a   Bádinez, Leonardo ^e   Olivares, Ruben ^a   Porcell, José ^a   Dueñas, Ricardo ^a  

^a Department of Oral and Maxillofacial Surgery   (Chile)

^b Instituto de Bio Oncología   (Chile)

^c UNIVERSIDAD MAYOR   (Chile)

^d UNIVERSIDAD DIEGO PORTALES   (Chile)

^e Centro Oncológico Fundación Arturo López Pérez   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CELL INFILTRATION; CENTRIFUGATION; CIRCULATING PROSTATE CELL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL GEL CENTRIFUGATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SERUM; TREATMENT FAILURE; AGED; BLOOD; CHILE; CLINICAL TRIAL; INCIDENCE; PATHOLOGY; PREVALENCE; PROGNOSIS; PROSTATE TUMOR; REPRODUCIBILITY; RISK ASSESSMENT; STATISTICS; TREATMENT OUTCOME; TUMOR EMBOLISM;

AGED; CHILE; HUMANS; INCIDENCE; MALE; NEOPLASTIC CELLS, CIRCULATING; PREVALENCE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84877270845     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/762064     Document Type: Article

References (18)

1. Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., Walsh P. C., Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association 1999 281 17 1591 1597 2-s2.0-0033526309 10.1001/jama.281.17.1591 (Pubitemid 29211767)
2. Amling C. L., Blute M. L., Bergstralh E. J., Seay T. M., Slezak J., Zincke H., Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. Journal of Urology 2000 164 1 101 105 2-s2.0-0033935812 (Pubitemid 30434268)
3. Morgan T. M., Lange P. H., Porter M. P., Lin D. W., Ellis W. J., Gallaher I. S., Vessella R. L., Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clinical Cancer Research 2009 15 2 677 683 2-s2.0-59449087476 10.1158/1078-0432.CCR-08-1754
4. Bain B. J., Bone marrow biopsy morbidity and mortality. British Journal of Haematology 2003 121 6 949 951 2-s2.0-0038607010 10.1046/j.1365-2141.2003. 04329.x (Pubitemid 36760316)
5. Murray N. P., Reyes E., Tapia P., Redefining micrometastasis in prostate cancer-a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. International Journal of Molecular Medicine 2012 30 4 896 904
6. Moreno J. G., Croce C. M., Fischer R., Monne M., Vihko P., Mulholland S. G., Gomella L. G., Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Research 1992 52 21 6110 6112 2-s2.0-0026481038
7. Murray N. P., Reyes E., Tapia P., Orellana N., Dueas R., Fuentealba C., Badinez L., Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy. Archivos Españoles de Urología 2011 64 10 961 971
8. Ploussard G., Agamy M. A., Alenda O., Allory Y., Mouracade P., Vordos D., Hoznek A., Abbou C. C., De La Taille A., Salomon L., Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. British Journal of Urology International 2011 107 11 1748 1754 2-s2.0-79956363454 10.1111/j.1464-410X.2010.09728.x
9. Palisaar R. J., Graefen M., Karakiewicz P. I., Hammerer P. G., Huland E., Haese A., Fernandez S., Erbersdobler A., Henke R. P., Huland H., Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. European Urology 2002 41 2 155 161 2-s2.0-0036487696 10.1016/S0302-2838(01)00025-2 (Pubitemid 35428881)
10. Jeon H. G., Bae J., Yi J. S., Hwang I. S., Lee S. E., Lee E., Perineural invasion is a prognostic factor for biochemical failure after radical prostatectomy. International Journal of Urology 2009 16 8 682 686 2-s2.0-68749102510 10.1111/j.1442-2042.2009.02331.x
11. Merrilees A. D., Bethwaite P. B., Russell G. L., Robinson R. G., Delahunt B., Parameters of perineural invasion in radical prostatectomy specimens lack prognostic significance. Modern Pathology 2008 21 9 1095 1100 2-s2.0-50249096170 10.1038/modpathol.2008.81
12. Yee D. S., Shariat S. F., Lowrance W. T., Maschino A. C., Savage C. J., Cronin A. M., Scardino P. T., Eastham J. A., Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. British Journal of Urology International 2011 108 4 502 507 2-s2.0-79961042041 10.1111/j.1464-410X. 2010.09848.x
13. Went P. T., Lugli A., Meier S., Bundi M., Mirlacher M., Sauter G., Dirnhofer S., Frequent EpCam protein expression in human carcinomas. Human Pathology 2004 35 1 122 128 2-s2.0-1642580506 10.1016/j.humpath.2003.08.026 (Pubitemid 38133932)
14. Paterlini-Brechot P., Benali N. L., Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Letters 2007 253 2 180 204 2-s2.0-34347353063 10.1016/j.canlet.2006.12.014 (Pubitemid 47017533)
15. Raimondi C., Gradilone A., Naso G., Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Research and Treatment 2011 130 2 449 455
16. Fizazi K., Morat L., Chauveinc L., High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Annals of Oncology 2007 18 3 518 521 2-s2.0-33847635749 10.1093/annonc/mdl419 (Pubitemid 46359632)
17. Millon R., Jacqmin D., Muller D., Guillot J., Eber M., Abecassis J., Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications. European Urology 1999 36 4 278 285 2-s2.0-0032822360 10.1159/000020005 (Pubitemid 29419442)
18. Tombal B., Van Cangh P. J., Loric S., Gala J. L., Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate 2003 56 3 163 170 2-s2.0-0042170360 10.1002/pros.10237 (Pubitemid 36918166)